A11 is a peptide derived from amino acid residues 20-30 of the ANXA1 N-terminus fused to the cell penetrating peptide CPP. A11 blocks ANXA1 competition with the E3 ubiquitin ligase Cbl for binding EphA2, enhancing Cbl-mediated EphA2 ubiquitination and degradation, and reducing the oncogenic mechanism of the ANXA1 - EphA2 interaction in nasopharyngeal carcinoma (NPC). A11 can suppress NPC cell growth in vitro and in vivo.
